Cytokinetics Inc and Royalty Pharma Funding Agreements Call Transcript
Good morning, and welcome, ladies and gentlemen, to the Cytokinetics conference call. At this time, I would like to inform you that this call is being recorded (Operator Instructions).
I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.
Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement regarding the structured financing with Royalty Pharma; then Ching Jaw, our SVP and Chief Financial Officer, will summarize the financial terms of each transaction, and will review our revised financial outlook. Robert will then provide final comments before opening the call for questions. At that time, we'll be joined by Fady Malik, EVP, Research and Development; Libby Schnieders, SVP, Business Development; and Andrew Callos, EVP and Chief Commercial Officer.
Please note that portions of the following discussion, including our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |